Skip to main content
. 2022 Dec 14;220(2):e20221717. doi: 10.1084/jem.20221717

Figure S1.

Figure S1.

Establishment of the PC fate mapping system. (A) Schematic representation of the generation of Blimp1-CreERT2 knock-in mice (left) and the PC-linage tracing system using Blimp1-CreERT2 R26-LSL-tdTomato mice (right). (B and C) Blimp1-CreERT2 R26-LSL-tdTomato mice were treated with tamoxifen for 3 d. (B) The expression of tdTomato in PCs (CD138+ TACI+) or B cells (B220+ CD138) in SPL or BM. Data are representative of three independent experiments. (C) The frequency of tdTomato+ cells in B cells or PCs in SPL and BM after tamoxifen treatment of Blimp1-CreERT2 R26-LSL-tdTomato mice. Three mice each were analyzed. (D and E) The frequency of each immune cell type expressing tdTomato. Three mice were analyzed. Data are representative of two independent experiments. (F) Absolute numbers of total BM PCs and SPL PCs analyzed in Fig. 1. Five to seven mice were analyzed at each time point. Data collected from 14 independent experiments are combined.